Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

GPCR

Structure Therapeutics Inc ADR

Apr 20 • 04:00PM ET

48.22

-2.53 -4.99 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BMY GILD BIIB AMGN MRNA NBIX NKTR INCY

| Held by: IBB SBIO FDG EWX LRNZ OZEM ONEQ GXC MID FMED

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.46	Insider Own	2.44%	Shs Outstand	70.84M	Perf Week	-11.12%
Market Cap	3.42B	Forward P/E	-	EPS next Y	-2.48	Insider Trans	0.00%	Shs Float	69.11M	Perf Month	-4.44%
Enterprise Value	1.98B	PEG	-	EPS next Q	-0.35	Inst Own	87.76%	Short Float	8.33%	Perf Quarter	-45.60%
Income	-141.43M	P/S	-	EPS this Y	-85.85%	Inst Trans	13.55%	Short Ratio	5.84	Perf Half Y	74.96%
Sales	0.00M	P/B	2.25	EPS next Y	-66.93%	ROA	-11.37%	Short Interest	5.76M	Perf YTD	-30.67%
Book/sh	21.41	P/C	2.36	EPS next 5Y	-	ROE	-11.88%	52W High	94.90 -49.19%	Perf Year	121.60%
Cash/sh	20.42	P/FCF	-	EPS past 3/5Y	-18.36% -40.35%	ROIC	-9.30%	52W Low	15.80 205.19%	Perf 3Y	99.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.16% 6.73%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-6.05%	Oper. Margin	-	ATR (14)	3.59	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	24.81	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	38.04	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	24.81	EPS Q/Q	188.26%	SMA20	-5.04%	Beta	-1.10	Target Price	109.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-17.48%	Rel Volume	0.80	Prev Close	50.75
Employees	220	LT Debt/Eq	0.00	Earnings	Feb 26 AMC	SMA200	10.74%	Avg Volume	985.61K	Price	48.22
IPO	Feb 03, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	414.51% -	Trades		Volume	785,811	Change	-4.99%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-26	Initiated	Wolfe Research	Peer Perform
May-02-25	Initiated	Citigroup	Buy	$60
Feb-28-25	Initiated	William Blair	Outperform
Jan-08-25	Initiated	Stifel	Buy	$50
Dec-04-24	Initiated	H.C. Wainwright	Buy	$80
Sep-23-24	Initiated	Morgan Stanley	Overweight	$118
May-21-24	Initiated	JP Morgan	Overweight	$65
Apr-09-24	Initiated	Cantor Fitzgerald	Overweight	$65
Oct-19-23	Initiated	JMP Securities	Mkt Outperform	$90
Jul-27-23	Initiated	Piper Sandler	Overweight	$58
May-25-23	Resumed	Jefferies	Buy	$34 → $41
Feb-28-23	Initiated	SVB Securities	Outperform	$33
Feb-28-23	Initiated	Jefferies	Buy	$34
Feb-28-23	Initiated	Guggenheim	Buy	$50
Feb-28-23	Initiated	BMO Capital Markets	Outperform	$40

Show Previous Ratings

Apr-14-26 04:05PM	Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel (GlobeNewswire)
Mar-17-26 03:20PM	This biotech is working on a GLP-1 pill that could be better than the Wegovy version (MarketWatch)
09:15AM	Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk (Proactive)
Mar-16-26 04:12PM	Structure Therapeutics Pops; But Can It Take On Lilly's Looming Obesity Pill? (Investor's Business Daily) +5.40%
10:46AM	Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate? (Barrons.com)
07:35AM	Loading…
07:35AM	Structures GLP-1 pill shows best-in-class potential in obesity trial (BioPharma Dive)
07:00AM	Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron (GlobeNewswire)
Mar-05-26 08:12AM	Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? (Zacks) -5.43%
Feb-26-26 04:02PM	Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights (GlobeNewswire)
Feb-25-26 08:40AM	Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead? (Zacks)
Feb-24-26 12:00PM	Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026 (Zacks)
Feb-23-26 01:25PM	Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin (Investor's Business Daily)
Feb-19-26 06:58AM	Structure Therapeutics (GPCR) Gained from Favorable Clinical Data (Insider Monkey)
Feb-18-26 07:22AM	Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition? (Zacks)
Feb-12-26 08:42AM	How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report (Zacks) -5.19%
10:49AM	Loading…
Feb-10-26 10:49AM	Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026 (Zacks)
Feb-04-26 09:30AM	Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook (Zacks)
Jan-23-26 09:18AM	Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It (Benzinga)
Jan-16-26 12:13PM	Jim Cramer on Structure Therapeutics: "I Don't Want to Touch It" (Insider Monkey)
10:47AM	LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling (Zacks)
Jan-15-26 11:35AM	Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why (Insider Monkey)
11:07AM	Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments (Benzinga)
10:17AM	How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results? (Zacks)
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-11-26 04:05PM	Can This Stock Double Again in 2026? (Motley Fool)
Jan-09-26 11:19AM	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (Reuters)
09:58AM	VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug (Zacks)
Jan-08-26 09:12AM	H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 (Insider Monkey)
Jan-05-26 10:37AM	LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? (Zacks) -7.85%
Dec-24-25 10:49AM	NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly? (Zacks)
10:46AM	Loading…
Dec-23-25 10:46AM	Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up (Zacks) +12.71%
Dec-22-25 10:11AM	What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 (Zacks)
Dec-17-25 08:30AM	Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity (GlobeNewswire)
Dec-15-25 10:32AM	CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval (Zacks)
Dec-12-25 10:37AM	NVO Down 42% Year to Date: Is This an Indication to Sell the Stock? (Zacks)
Dec-11-25 04:28PM	Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss (Investor's Business Daily)
04:01PM	Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs (GlobeNewswire)
10:23AM	Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge? (Zacks)
08:10AM	Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7% (Investor's Business Daily)
Dec-10-25 10:17AM	Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies? (Zacks)
Dec-09-25 11:15PM	Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants (GlobeNewswire)
02:23PM	Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial (Insider Monkey)
11:15AM	In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera? (Investor's Business Daily)
09:27AM	GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron (Zacks)
Dec-08-25 08:15PM	Why Structure Therapeutics Stock Doubled and Then Some on Monday (Motley Fool) +102.49%
04:15PM	Structure Therapeutics Soars; CEO Says It Could Have 'Best In Class' Weight-Loss Drug (Investor's Business Daily)
04:01PM	Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants (GlobeNewswire)
12:46PM	Obesity Biotechs' Gains Hit Shares of Eli Lilly, Novo Nordisk (Barrons.com)
10:36AM	Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill (The Wall Street Journal)
09:12AM	Structure details positive trial data for a weight-loss pill, and the stock rockets (MarketWatch)
08:00AM	Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-07-25 06:20PM	Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 (GlobeNewswire)
Nov-16-25 10:14PM	BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts (Insider Monkey)
Nov-06-25 04:01PM	Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Oct-30-25 02:11PM	Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks. (Barrons.com) +8.96%
Oct-24-25 11:39AM	NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? (Zacks)
Sep-21-25 09:23AM	Structure Therapeutics Inc. (GPCR) Eyes Major 2025 Catalyst With Phase 2b Obesity Data (Insider Monkey)
Sep-12-25 08:15AM	This Under-the-Radar Healthcare Stock Could Soar in 2026 (Motley Fool)
Sep-02-25 08:30AM	Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-19-25 04:05PM	Viking Therapeutics Crashes 42% On Mixed Results For Its Weight-Loss Pill (Investor's Business Daily) -5.81%
Aug-11-25 08:22PM	Structure Therapeutics To Present Late-Breaking ADA Data on Oral Amylin Agonist ACCG-2671 (Insider Monkey) +7.36% +7.02%
Aug-07-25 04:20PM	Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying (Investor's Business Daily)
09:55AM	Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors (Benzinga)
09:01AM	Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. (Investor's Business Daily)
Aug-06-25 04:01PM	Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Jun-24-25 05:42PM	Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT (Insider Monkey)
Jun-20-25 07:30PM	Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 (GlobeNewswire)
May-29-25 04:05PM	Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences (GlobeNewswire)
May-08-25 04:05PM	Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Apr-25-25 04:31PM	Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts? (Insider Monkey)
Apr-21-25 08:37AM	LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study (Zacks) +6.16%
Apr-18-25 11:25AM	Eli Lilly jumps as results from weight-loss pill study rival competitors (TipRanks)
10:26AM	JPMorgan says Lilly data highly favorable for Structure Therapeutics (TipRanks)
Apr-15-25 10:35AM	Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill (TipRanks)
10:00AM	NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback (Zacks)
Apr-14-25 11:12AM	Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today (Motley Fool) +19.18%
Mar-24-25 07:21PM	Structure Therapeutics CEO on latest GLP-1 developments (CNBC TV)
Mar-20-25 09:28AM	Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate (SeekingAlpha)
Mar-03-25 04:20PM	AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. (Investor's Business Daily) -5.94%
Feb-27-25 04:05PM	Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights (GlobeNewswire) +14.79%
Feb-14-25 07:56AM	Why Structure Therapeutics Stock Was Stumbling This Week (Motley Fool)
Jan-30-25 08:30AM	Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences (GlobeNewswire)
Dec-18-24 10:25AM	Merck Licenses a Weight-Loss Pill. Its Bad News for Obesity Biotechs. (Barrons.com) -11.37%
Dec-17-24 04:01PM	Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity (GlobeNewswire)
Dec-16-24 01:33PM	Is Structure Therapeutics Inc. (GPCR) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-08-24 06:05AM	Jefferies Predicts Up to ~1000% Surge for These 2 Strong Buy Stocks (TipRanks)
Nov-27-24 10:15AM	Why Is Structure Therapeutics Inc. (GPCR) Among the Best Up and Coming Stocks to Buy According to Analysts? (Insider Monkey)
Nov-22-24 07:45AM	Structure Therapeutics Inc. (GPCR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey) +11.00%
Nov-15-24 08:30AM	Structure Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) -9.34%
Nov-13-24 04:05PM	Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
04:01PM	Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity (GlobeNewswire)
Oct-31-24 08:30AM	Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2024 (GlobeNewswire) +8.69%
Oct-24-24 07:58PM	GPCR drugmaker Septerna amasses $288M in IPO (BioPharma Dive)
Oct-16-24 08:45AM	Structure Therapeutics (GPCR): Innovating Oral Therapies for Obesity and Diabetes (Insider Monkey) +7.41%
Oct-09-24 09:55AM	Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect? (Zacks)
Oct-04-24 08:00AM	As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer (Investor's Business Daily)
Sep-29-24 02:05AM	Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now? (Insider Monkey)
Sep-20-24 01:17PM	High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill (The Wall Street Journal) +8.18%
Sep-17-24 04:05PM	Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer (GlobeNewswire)

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GPCR

Structure Therapeutics Inc ADR

Upgrade your Finviz experience